Zoonotic Disease Treatment Market Report 2025

This Zoonotic Disease Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The zoonotic disease treatment market size has grown strongly in recent years. It will grow from $39.71 billion in 2024 to $42.64 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the emergence of major zoonotic outbreaks, urbanization, and habitat encroachment, one health approach, increased surveillance and reporting, globalization, and increased travel and public awareness and education.

The zoonotic disease treatment market size is expected to see strong growth in the next few years. It will grow to $55.92 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to climate change and environmental factors, government and international funding, advancements in medical technology, regulatory support and streamlined approvals, and collaborative research and development. Major trends in the forecast period include the development of broad-spectrum antivirals, strengthening global health infrastructure, advances in diagnostic technology, growth in vaccine development platforms, and focus on preventive measures.

The growing demand for animal proteins is expected to drive the growth of the zoonotic disease treatment market in the coming years. Animal proteins, derived from sources such as meat, dairy, eggs, and fish, provide all essential amino acids required for human health. This rise in demand is attributed to factors like the increasing global population, higher income levels, urbanization, and greater awareness of the nutritional benefits of animal-based foods. Zoonotic disease treatments are crucial for managing diseases associated with animal proteins, helping to understand transmission pathways, develop effective therapies, and implement preventive measures to reduce public health risks. For example, in July 2023, a report from the Organization for Economic Co-operation and Development and the Food and Agriculture Organization highlighted that global meat consumption is projected to grow at an annual rate of 0.1%. This increase is mainly driven by rising demand in middle and lower-income countries, with poultry expected to contribute nearly half of the total growth in meat production by 2032.

Major companies in the zoonotic disease treatment market are increasingly investing in advanced diagnostic technologies and treatment protocols to improve the identification and management of zoonotic diseases. These efforts include developing tools such as PCR kits for faster identification of zoonotic pathogens and implementing targeted therapeutic interventions. For example, in October 2023, BioPerfectus, a China-based biotechnology company specializing in diagnostic solutions, expanded its Zoonotic Infectious Diseases Total PCR Solution by adding thirteen new members. This enhancement aims to strengthen its diagnostic capabilities for zoonotic diseases, which are responsible for more than 60% of known infectious diseases and 75% of emerging infections. The initiative is designed to improve health security and response, especially as climate change facilitates the spread of infectious diseases to new regions. With these new products, BioPerfectus aims to enable quicker diagnoses and better management of zoonotic infections, emphasizing the need for proactive public health measures.

In May 2022, Ceva Santé Animale, a veterinary pharmaceutical company headquartered in France, purchased Artemis Technologies Inc. for an undisclosed sum. This strategic acquisition bolsters Ceva's current rabies portfolio and extensive proficiency in manufacturing oral rabies vaccines and conducting rabies vaccination campaigns throughout Europe and other territories. Artemis Technologies Inc., based in Canada, specializes in supplying vaccines for zoonotic diseases.

Major companies operating in the zoonotic disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboretories Inc., Hikma Pharmaceuticals PLC., Ceva Santé Animale, Vir Biotechnology Inc., Virbac, Vetoquinol S.A., BioCryst Pharmaceuticals Inc, Heska Corporation.

North America was the largest region in the zoonotic disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zoonotic disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the zoonotic disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment for zoonotic diseases encompasses medical interventions and therapies designed to diagnose, manage, and prevent illnesses caused by pathogens transmitted between animals and humans. This treatment regimen typically combines medication, vaccination, hygiene protocols, and control measures to minimize transmission and alleviate the impact of these infections on both animal and human communities.

The primary diseases addressed in zoonotic disease treatment include rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and others. Rabies, for instance, is a viral illness characterized by acute inflammation of the brain in humans and other mammals, commonly transmitted through the bite of an infected animal. Zoonotic disease treatment encompasses various drug classes such as anti-fungal, anti-bacterial, antibiotics, and others, targeting diverse agents such as bacteria, viruses, nematodes, rodents, ticks, and others. Administration routes comprise oral, topical, and others, with distribution occurring through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The zoonotic disease treatment market research report is one of a series of new reports that provides zoonotic disease treatment market statistics, including zoonotic disease treatment industry global market size, regional shares, competitors with a zoonotic disease treatment market share, detailed zoonotic disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the zoonotic disease treatment industry. This zoonotic disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The zoonotic disease treatment market consists of revenues earned by entities by providing services such as vaccinations, antimicrobial therapy, supportive care, and vector control. The market value includes the value of related goods sold by the service provider or included within the service offering. The zoonotic disease treatment market also includes sales of diagnostic kits, antimicrobial medications (antiparasitic, immunomodulators), and vector control products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.